Why Moderna Stock Skyrocketed Today
7 Articles
7 Articles
An experimental vaccine developed by Moderna and Merck offers new hope in oncology after demonstrating that it can prevent relapse in patients with high-risk melanoma. Administered in combination with Keytruda — an immunotherapy already widely used — innovative treatment brings a new therapeutic approach for people with skin cancer.
An important step forward in the investigation of therapeutic vaccines against cancer. Moderna and Merck announced on Wednesday positive results of the phase 3 clinical trial INTerpath-001, which studies a personalized therapy of mRNA against melanoma. The treatment, called intismeran autogene, is given along with the immunotherapy pembrolizumab in patients with stage IIB to stage IV skin melanoma whose tumor had been completely removed by surge…
New York, USA.- The pharmaceuticals Merck and Moderna reported on Wednesday, August 19, positive results of their experimental vaccine against messenger RNA-based skin cancer. Combined with Keytruda (Merck's immunotherapy), the vaccine met the primary goal and a relevant secondary objective in a Phase 3 study in high-risk melanoma already operated. It is the first Phase 3 trial with a positive outcome both for a neoantigen therapy tailored to ea…
Coverage Details
Bias Distribution
- 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
